1 / 17

WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691-701 (2004)

WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691-701 (2004). 報告同學 : 陳宜芳 組 員 : 陳宜芳 陳彥任 葉儀君 莊健盈 王怡婷 黃冠誠 林佩儒 邱敏熙 楊瑞珠 楊玫琳 曾宜萱 徐袁章. Wnt signalling pathway. WNT/ β -catenin signalling. WNT/calcium signalling.

ryu
Télécharger la présentation

WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691-701 (2004)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691-701 (2004) 報告同學: 陳宜芳 組 員: 陳宜芳 陳彥任 葉儀君 莊健盈 王怡婷 黃冠誠 林佩儒 邱敏熙 楊瑞珠 楊玫琳 曾宜萱 徐袁章

  2. Wnt signalling pathway WNT/β-catenin signalling WNT/calcium signalling

  3. Mutations in Wnt3 are linked to tetra-amelia A nonsense mutation in Wnt3 causes tetra-amelia---- the loss of all four limbs. sFRP3 and osteoarthritis A SNP is associated with osteoarthritis in females. This SNP is found in secreted Frizzled-related protein 3 (sFRP3) and reduces the ability of sFRP3 to antagonize Wnt signalling Wnt signalling might be elevated in osteoarthritis

  4. Chromosomal duplication of Wnt4 and an intersex phenotype Wnt4 overexpression  disrupts normal testicular vasculature  inhibits testosterone synthesis by repressing steroidogenic factor 1 / β-catenin synergy. Wnt4 acts as an anti-male factor by interfering with β-catenin functions.

  5. Wnt4 and renal development and disease WNnt4 is a key role in renal tubule formation. A rat model of acute renal failure  Wnt4 overexpression After renal injury CNP (C-type natriuretic peptide) gene expression is activated and correlates with Wnt4 expression. WNT/β-catenin signalling is involved in polycystic kidney disease (PKD)  PKD1 gene mutation  Wnt4 overexpression has been reported in polycystic kidneys in mice.

  6. Wnt5a - a tumor suppressor gene and a modulator of metastasis • Loss of Wnt5a in mammary epithelial cells • phenotypic transformation↑ • blocked by overexpression of Wnt5a • Wnt5a signals through Wnt/calcium pathway • suppress cyclin D1 expression • negatively regulate B cell proliferation. Wnt5a, through its activation of PKC  a highly motile and invasive phenotype.

  7. Wnt1 and the neurodevelopmental hypothesis of schizophrenia Wnt1 overexpression → altered cell adhesion, synaptic rearrangement and plasticity in the brains of people with schizophrenia. SNPs in FZ3 are associated with susceptibility to schizophrenia. Dsh1/Dvl1 -/- mice produces behavioural defects, further linking the Wnt pathway to the modulation of brain activity.

  8. Altered function of Frizzled and LRP5/6 • Loss-of-function mutations in FZ4 and LRP5 are linked to familial exudative vitreoretinopathy (FEVR) • a truncated protein that acts in a dominant– negative manner  oligomerize with wild-type FZ receptors  trap them in the endoplasmic reticulum • Whether FZ4 signalling is reduced in FEVR patients?

  9. Altered function of Frizzled and LRP5/6 • Activating mutations in LRP5 are linked to high bone mass • an 18-year-old female Nebraska highschool student • An amino-acid change in the extracellular domain of LRP5  linked to this high bone mass phenotype  weak activation of the β-catenin pathway • treatments for osteoporosis? • Loss-of-function mutations in LRP5 are linked to low bone mass and eye defects

  10. Altered function of cytoplasmic components Activation of b-catenin signalling and cancer. • mutations in the tumour suppressor APC • gain-of-function mutations in the N-terminal • phsphorylation sites • loss-of-function mutations in AXIN • non-small-cell lung cancer: • DSH/DVL genes overexpressed • siRNA reduced expression AXIN2, familial tooth agenesis and colon cancer. Am. J. Hum. Genet. 74:1043–1050, 2004

  11. Altered function of cytoplasmic components Mutations linked to tuberous sclerosis activate b-catenin. • Tuberous sclerosis complex (TSC) genes Tsc1 or Tsc2 • Proteins encoded from TSC genes from complexes and • reduce the level of b-catenin • TSC complex co-immunoprecipitates with AXIN and • GSK3 Activated b-catenin signalling in skin. Development, 130: 2793, 2003

  12. Altered function of cytoplasmic components Activated b-catenin signalling in pulmonary fibrosis AJP 162: 1393, 2003 Attenuated b-catenin signaling in Alzheimer disease TRENDS in Pharmacological Sciences 24: 233, 2003

  13. Altered function of cytoplasmic components Cardiovascular disease PNAS, 100: 5834, 2003

  14. Therapeutic modulation of WNT pathways

  15. Wnt/b-catenin in the morphogenesis of chicken liver Dev. Biol.266, 109−122

  16. Wnt signalling in the stem cells or progenitors Nature434, 843-850 (2005)

More Related